Koo and colleagues are now working
on novel therapeutic approaches for targeted interventions, which can be potentially developed for clinical use.
Not exact matches
We rely
on high quality basic and translational respiratory science, such as these latest findings, to develop
novel therapeutic approaches for the millions of patients suffering from devastating and often fatal respiratory conditions.
The second focus
on my research is the development of
novel therapeutic vaccine
approaches for cancer.
Our group is specifically working
on improvement of islet isolation and transplantation protocols in clinical practice and the development of
novel therapeutic options in the field of beta cell replacement with a clear translational «bench to bedside»
approach by linking experimental research with preclinical and clinical work:
Conference mainly focuses
on: • Translational medicine
approaches in drug discovery & development • Cardio - Vascular Translational Medicine • Translational Haematology • Translational therapeutics /
Novel therapeutic technologies • Clinical and Translational Oncology • Translational Neuroscience...
Our group has 3 major goals: Develop
novel therapeutic approaches based
on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify
novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate
novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus
on multiple myeloma
Dr Peter Barlow: «Dr Peter Barlow is funded by a grant from the Chief Scientist Office (Scotland)
on a project investigating
novel therapeutic approaches for respiratory viral infections.»
«Without them, and without our partners
on the U-M Neurosurgery team, and donors to the Phase One Foundation that support our work, we wouldn't be able to take this important step in testing this
novel therapeutic approach.»